https://www.healio.com/news/pulmonology/20220921/vilobelimab-may-reduce-mortality-in-patients-with-severe-covid19-pneumonia
0
0
9/21/22 at 1:55pm
Organization
Healio
Authors
Treatment with vilobelimab reduced mortality at 28 to 60 days in patients with severe COVID-19 pneumonia without increasing infections, according to data presented at the European Respiratory Society International Congress.Vilobelimab (InflaRx) is a first-in-…
Create an account
or login to join the discussion